Abstract: The present invention relates to the field of immunological methods, more precisely to the field of detection methods for antibodies against double-stranded DNA (dsDNA) for diagnostics of chronic autoimmune diseases, such as systemic lupus erythematosus (SLE). The fluorometric immunoassay method for detection of anti-dsDNA solves the technical problem of designing a method for detection of the aforesaid antibodies, which would be faster, cheaper and less toxic as the standard Farr-RIA method, but would have the same diagnostic specificity (which is 100%) and improved diagnostic sensitivity (for 3%). Detection of anti-dsDNA is based on detection of fluorescence in two fractions of samples, in the supernatant and in the sample with a precipitate, which contains immune complexes composed of added dsDNA and anti-dsDNA present in the patient's serum, wherein the detected fluorescence is a consequence of binding fluorescent dyes with dsDNA bound in the complexes or with free dsDNA.

Abstract: The invention relates to a method for detecting and measuring the presence of mono-nucleosomes and oligo-nucleosomes and nucleosomes that contain particular histone variants and the use of such measurements for the detection and diagnosis of disease. The invention also relates to a method of identifying histone variant biomarkers for the detection and diagnosis of disease and to biomarkers identified by said method.

Abstract: The present invention relates to a method for detecting molecules.

Abstract: The present invention is related to a method for detecting a protein comprising: (1) providing a fusion protein, wherein the fusion protein comprises the protein which is fused with a secondary antibody detected protein tag, wherein the secondary antibody detected protein tag comprises at least one epitope selected from the Fc region of at least one primary antibody which is capable of being detected by a corresponding secondary antibody; (2) contacting the fusion protein with a secondary antibody which binds to the secondary antibody detected protein tag to form a protein/antibody complex; and (3) detecting the protein/antibody complex.

Abstract: Methods are disclosed for identifying one or more proteins or polypeptides comprised by a sample. The methods comprise determining binding of each polypeptide with respect to each binding pool of a plurality of binding pools, wherein each binding pool comprises one or more probes which bind a structure comprised by a protein or polypeptide. In some aspects, polypeptides can be denatured and separated into individual polypeptide strands and immobilized on a solid support prior to determining binding of the binding pools. A protein, polypeptide or polypeptide strand can be identified by searching, in at least one database, for a protein or polypeptide sequence comprising binding pool targets either identical to or most similar to the binding pool targets comprised by the protein, polypeptide or polypeptide strand to be identified. Kits for identifying proteins, polypeptides and polypeptide strands are also disclosed.

Abstract: This present invention relates to a method for selecting an antigen-specific hybridomas comprising catching a monoclonal antibody secreted from a hybridoma by using a plasma cell's cell-surface expression molecular on the surface of the hybridoma, providing an antigen with a label to react with the hybridoma, and selecting the hybridoma expressing the label to obtain an antigen-specific hybridoma. In other words, the hybridoma can express the label because of the monoclonal antibody combining with the antigen. Accordingly, the method of this present invention can quickly select the antigen-specific hybridoma.

Abstract: Provided herein and methods and kits for identifying inhibitors of SUMOylation. The provided methods include contacting a candidate agent with (i) a SUMO-conjugating peptide comprising an N-terminal linker and a detectable tag, and (ii) a SUMO comprising a metal complex, under conditions that allow binding between the SUMO-conjugating peptide and the SUMO, and detecting the detectable tag thereby determining the level of binding between the SUMO-conjugating peptide and SUMO. A reduced level of binding as compared to the level of binding in the absence of the candidate agent indicating the agent inhibits SUMOylation.

Abstract: Methods, compositions, and reaction mixtures are provided for identifying a T cell receptor (TCR) and an epitope peptide that specifically binds the TCR. Methods, compositions, and reaction mixtures are also provided for identifying a plurality of T cell receptors and corresponding epitope peptides that specifically bind the T cell receptors. In some cases, the plurality of T cell receptors and corresponding epitope peptides can be identified in a highly parallel manner.

Abstract: The present invention relates to a novel antigen binding protein, in particular a monoclonal antibody, capable of binding specifically to the protein Axl as well as the amino and nucleic acid sequences coding for said protein. From one aspect, the invention relates to a novel antigen binding protein, or antigen binding fragments, capable of binding specifically to Axl and, by inducing internalization of Axl, being internalized into the cell. The invention also comprises the use of said antigen binding protein as an addressing product in conjugation with other anti-cancer compounds, such as toxins, radio-elements or drugs, and the use of same for the treatment of certain cancers.

Abstract: The present invention provides novel methods for the detection of antibodies, in particular, blood group antibodies. The methods of this invention may be applied to pre-transfusion blood compatibility testing for the detection of incompatibility between donor units (comprising donor red blood cells (erythrocytes)) and a recipient.

Abstract: The application discloses new biomarkers and methods useful in the diagnosis, prognosis and/or monitoring of, or as a therapeutic or research target for, solid tumor cancers, such as colorectal cancer, based on measuring the biomarkers; and related kits and devices.

Abstract: The present invention provides a method for measuring a modified nucleobase that increases detection sensitivity for the modified nucleobase in a target nucleic acid. Specifically, the present invention provides a method for measuring a modified nucleobase including: (1) incubating a nucleic acid sample, a capture probe, and a guide probe in a solution; and (2) measuring the modified nucleobase using an antibody against the modified nucleobase in the solution obtained at (1). The present invention also provides a kit for measuring a modified nucleobase including: (I) a guide probe; and (II) a capture probe and/or an antibody against the modified nucleobase.

Abstract: Methods for preparation of cells for analysis of biomarkers are disclosed. In one aspect, the method for preparation of cells for analysis of biomarkers includes contacting a sample that contains a population of cells with at least one modulating substance at a first temperature, thereby producing a modulated cell population; contacting the modulated cell population with at least one antibody that is directed to a cell surface biomarker at a second temperature that is lower than the first temperature, thereby producing an extracellularly stained cell population; and contacting the extracellularly stained cell population with one or more reagents that fixes and permeabilizes the cells, thereby producing a fixed and permeabilized cell population.

Abstract: The present invention relates to methods for determining a binding and/or functional interaction of a protein of interest with a nucleosomal substrate wherein at least one of the histone types of the nucleosomal substrate has a homogenous post-translational modification pattern. Further, the invention relates to nucleosomal substrates, wherein at least one of the histone types of the nucleosomal substrate has a homogenous post-translational modification pattern, and to methods for providing such nucleosomal substrates.

Abstract: A method for (a) diagnosing or monitoring kidney function in subject or (b) diagnosing kidney dysfunction in a subject or (c) predicting or monitoring the risk of an adverse events in a diseased subject or (d) predicting or monitoring the success of a therapy or intervention comprising determining the level of Pro-Enkephalin (PENK) or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said subject; and correlating said level of Pro-Enkephalin or fragments thereof with (a) kidney function in a subject or (b) kidney dysfunction in said subject or (c) enhanced risk of adverse events or (d) success of a therapy or intervention in a diseased subject.

Abstract: The methods and compositions described herein relate to the measurement of factor VIII (fVIII) levels and/or activity.

Abstract: This disclosure provides, in one aspect, a method for analyzing a sample from a subject for a biomarker that is indicative of the subject's immune response to ?-glucan. Generally, the method includes obtaining a biological sample from a subject, analyzing the sample for a biomarker anti-?-glucan antibody compared to a reference standard, computing a Relative Antibody Unit (RAU) value for anti-?-glucan antibody in the sample, and identifying the subject as biomarker positive if the RAU value is greater than a predetermined RAU value for the biomarker anti-?-glucan antibody.

Abstract: The invention provides binding agents and assays tor insulin signal peptide. The agents and assays are useful in methods tor predicting, diagnosing, assessing or monitoring acute cardiac disorders, glucose handling disorders and diabetes in a subject. Also provided are nucleotides, polypeptides, and kits useful in the methods of the invention.

Abstract: The present invention provides a technique that suppresses a background value of a detection signal to construct an immunoassay system that detects a modified nucleobase. Specifically, the present invention provides a method for measuring a modified nucleobase including incubating a nucleic acid sample, a capture probe, and a solid phase probe in a solution and measuring a modified nucleobase using an antibody against the modified nucleobase in the obtained solution. The present invention also provides a kit for measuring a modified nucleobase including a capture probe, a solid phase probe, and an antibody against a modified nucleobase.

Abstract: The invention relates to a method of determining the inflammatory disorder status of a subject comprising detecting the presence or absence, or the level, of (i) citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C; and/or (ii) autoantibodies with specificity for citrullinated tenascin-C and/or one or more fragments of citrullinated tenascin-C, in a sample from said subject.